Search Results - "Gehr, T"

Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation by Ghosh, S S, Massey, H D, Krieg, R, Fazelbhoy, Z A, Ghosh, S, Sica, D A, Fakhry, I, Gehr, T W B

“…TNF-alpha and NF-kappaB play important roles in the development of inflammation in chronic renal failure (CRF). In hepatic cells, curcumin is shown to…”
Get more information

Curcumin and enalapril ameliorate renal failure by antagonizing inflammation in 5/6 nephrectomized rats: role of phospholipase and cyclooxygenase by Ghosh, S S, Krieg, R, Massey, H D, Sica, D A, Fakhry, I, Ghosh, S, Gehr, T W B

“…Previously, we showed that curcumin prevents chronic kidney disease (CKD) development in nephrectomized (Nx) rats when given within 1 wk after Nx (Ghosh SS,…”
Get more information

MicroRNA Profiles in Allograft Tissues and Paired Urines Associate With Chronic Allograft Dysfunction With IF/TA by Scian, M. J., Maluf, D. G., David, K. G., Archer, K. J., Suh, J. L., Wolen, A. R., Mba, M. U., Massey, H. D., King, A. L., Gehr, T., Cotterell, A., Posner, M., Mas, V.

“…Despite the advances in immunosuppression, renal allograft attrition over time remains unabated due to chronic allograft dysfunction (CAD) with interstitial…”
Get full text

Analysis of the pharmacological properties of chicken melanocortin-2 receptor (cMC2R) and chicken melanocortin-2 accessory protein 1 (cMRAP1) by Barlock, Travis K, Gehr, Deshae T, Dores, Robert M

“…Highlights • Expression of Gallus gallus MC2R in CHO requires co-expression with G. gallus MRAP1. • G. gallus MC2R can be activated by hACTH(1-24), but not by…”
Get full text

The fading of reported effectiveness. A meta-analysis of randomised controlled trials by Gehr, Bernhard T, Weiss, Christel, Porzsolt, Franz

“…The "real" effect size of a medical therapy is constant over time. In contrast, the effect size reported in randomised controlled trials (RCTs) may change over…”
Get full text

The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency by Gehr, T W, Tenero, D M, Boyle, D A, Qian, Y, Sica, D A, Shusterman, N H

“…Carvedilol, a chiral compound possessing nonselective beta- and alpha1-blocking activity, is used for the treatment of hypertension and congestive heart…”
Get full text

Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study by Jones, M, Hagen, T, Boyle, CA, Vonesh, E, Hamburger, R, Charytan, C, Sandroni, S, Bernard, D, Piraino, B, Schreiber, M, Gehr, T, Fein, P, Friedlander, M, Burkart, J, Ross, D, Zimmerman, S, Swartz, R, Knight, T, Kraus, A, McDonald, L, Hartnett, M, Weaver, M, Martis, L, Moran, J

“…A peritoneal dialysis (PD) solution containing 1.1% amino acids as the osmotic agent was evaluated in a 3-month randomized, prospective, open- label study in…”
Get full text

Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end‐stage renal disease by BROPHY, D. F., MARTIN, E. J., GEHR, T. W. B., BEST, A. M., PAUL, K., CARR, M. E.

“…Background: Patients with end‐stage renal disease (ESRD) who receive enoxaparin are at increased risk for adverse bleeding episodes. This phenomenon appears to…”
Get full text

Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction by Brophy, D. F., Martin, E. J., Best, A. M., Gehr, T. W. B., E. Carr, M.

“…Antifactor Xa activity is the gold standard monitoring parameter for low molecular weight heparin (LMWH) derivatives. It is frequently measured in high‐risk…”
Get full text

Chronically increased intra-abdominal pressure produces systemic hypertension in dogs by Bloomfield, G.L, Sugerman, H.J, Blocher, C.R, Gehr, T.W.B, Sica, D.A

“…OBJECTIVE: Determine if increased intra-abdominal pressure (IAP) alone can cause systemic hypertension in a chronic canine model. DESIGN: Evaluate effects of…”
Get full text

The Pharmacokinetics of Subcutaneous Enoxaparin in End-Stage Renal Disease by Brophy, Donald F., Wazny, Lori D., Gehr, Todd W. B., Comstock, Thomas J., Venitz, Jürgen

“…Study Objective. To evaluate the pharmacokinetics of enoxaparin in end‐stage renal disease (ESRD), and determine if dosage reduction is necessary to maintain…”
Get full text

Diuretic combinations in refractory oedema states : pharmacokinetic-pharmacodynamic relationships by SICA, D. A, GEHR, T. W. B

“…Diuretic resistance is encountered in a number of disease states, such as chronic renal failure, nephrotic syndrome, congestive heart failure (CHF) and…”
Get full text

The pharmacokinetics of pravastatin in patients on chronic hemodialysis by GEHR, T. W. B, SICA, D. A, SLUGG, P. H, HAMMETT, J. L, RAYMOND, R, FORD, N. F

“…The single-dose and steady-state pharmacokinetics of the HMG CoA reductase inhibitor pravastatin and its two metabolites, SQ 31,906 and SQ 31,945, were…”
Get full text

Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution by Jones, M R, Gehr, T W, Burkart, J M, Hamburger, R J, Kraus, Jr, A P, Piraino, B M, Hagen, T, Ogrinc, F G, Wolfson, M

“…Losses of nutrients into dialysate may contribute to malnutrition. Peritoneal dialysis (PD) patients are reported to lose 3-4 g/day of amino acids (AAs) and…”
Get more information

Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease by SICA, D. A, GEHR, T. W. B, FERNANDEZ, A

“…The effective treatment of hypertension is an extremely important consideration in patients with end-stage renal disease (ESRD). Virtually any drug class--with…”
Get full text

Pharmacokinetics and blood pressure response of losartan in end-stage renal disease by SICA, D. A, HALSTENSON, C. E, GEHR, T. W. B, KEANE, W. F

“…Losartan is a selective angiotensin AT1 receptor antagonist currently employed in the management of essential hypertension. This compound is in common use in…”
Get full text

The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis by Sica, Domenic A., Marino, Maria R., Hammett, Janice L., Ferreira, Irene, Gehr, Todd W. B., Ford, Neville F.

“…Purpose An open‐label, multiple‐dose, parallel‐group study was conducted to evaluate the pharmacokinetics of the angiotensin II receptor antagonist irbesartan…”
Get full text

Direct Vasodilators and their Role in Hypertension Management: Minoxidil by Sica, Domenic A., Gehr, Todd W.B.

“…Minoxidil is a direct vasodilator that has been in use for over two decades. It is used primarily to reduce blood pressure in hypertensives who have been…”
Get full text

E030 The antihypertensive and neurohumoral effects of losartan (LOS) in end-stage renal disease (ESRD) peritoneal dialysis (PD) patients by Gehr, T., Sica, D., Pedro, P., Ruddley, J.

Get full text

Pharmacodynamics(PD) and kinetics (PK) of bivalirudin (BIV) in renal failure (RF) and hemodialysis (HD) by Irvin, W., Sica, D., Gehr, T., McAllister, A., Rogge, M., Charenkavanich, S., Adelman, B.

“…Clinical Pharmacology & Therapeutics (1999) 65, 202–202; doi:…”
Get full text